

Date and Time: **Wednesday 25th April 2012 (10:00–16:00h)**

Minutes: Draft

MI: Secondary Prevention (Update) Guideline Development Group Meeting 2

Place: *Boardroom, National Clinical Guideline Centre, 180 Great Portland Street, London W1W 5QZ*

Present:

Phil Adams	Emeritus Consultant Cardiologist, GDG Chair
Maria Wray	Patient member
John Walsh	Patient member
Joseph Mills	Consultant cardiologist
Jerry Murphy	Consultant cardiologist
Kathryn Carver	Cardiac rehabilitation lead nurse
Caroline Levie	Cardiovascular clinical team lead
Linda Speck (LJS)	Consultant clinical health psychologist
William Cunningham	General Practitioner
Ivan Bennett	General Practitioner
Jennifer Jones	Honorary superintendent physiotherapist
Paul Wright	Principal clinical pharmacist

In attendance:

<p>NICE Staff: Clifford Middleton</p> <p>NCGC Staff: Liz Avital Katie Jones Julie Neilson Kate Lovibond Leanne Saxon Joanna Ashe</p>	<p>Guidelines Commissioning Manager</p> <p>Associate Director Project Manager Senior Research Fellow Health Economics Lead Research Fellow Senior Information Scientist</p>	<p>(Present for notes 1–11)</p>
--	---	---------------------------------

Notes

1. The Chair welcomed the group to the first MI: Secondary Prevention (update) Development Group Meeting (GDG1) and asked attendees to introduce themselves. Apologies were received from Sanjay Ramdany (GDG). The Chair requested updates to the existing declarations of interests from GDG members. The following declarations were made:

PA: None
WC: None

Notes

KC: None

KL: None

JJ: Declared a non-specific non-personal pecuniary interest in that, in her capacity as BACPR President, she was involved in obtaining funding from Roche and Abbott for the BACPR Conference.

LJS: Declared a non-specific non-personal pecuniary interest in that, in her capacity as BACPR Treasurer, she was involved in obtaining funding from Roche and Abbott for the BACPR Conference.

PW: No additional declarations.

MW: None

CL: None

JMills: Declared a specific personal pecuniary interest in that he had attended, and received payment for, an Abbott advisory board on omega-3 fatty acids. It was agreed that JMills would withdraw from the discussions on omega-3 fatty acids.

LA: None

JMurphy: Declared a non-specific personal pecuniary interest in that he had attended, and received payment for, an MSD advisory board on the role of the lipid lowering agent Ezetemibe in the prevention of cardiovascular disease. It was agreed that this should be declared but no action was required.

IB: Declared a non-specific pecuniary interest in that he had attended, in 2010-2011, and received payment for, a GSK advisory board on eptifibatide and a Servier advisory board on ivabradine. It was agreed that no action was required given the date of these meetings. IB declared a specific personal pecuniary interest in that, in 2012, he had attended the American Academy of Cardiology conference as a guest of Boehringer Ingelheim and had received travel, accommodation and expenses. It was agreed that IB would need to declare and withdraw from any questions on dabigatran.

JF: None

CM: None

2. **GRADE**

A presentation was delivered on GRADE.

3. **Supporting the GDG to make recommendations**

A presentation was given on making recommendations.

4. **Protocols**

The GDG discussed the content of protocols for future clinical evidence reviews.

5. **Evidence review: Oily fish**

The GDG reviewed the clinical and health economic evidence for oily fish for the secondary prevention of myocardial infarction.

6. **Evidence review: Omega-3**

The GDG reviewed the clinical and health economic evidence for omega-3 fatty acids for the secondary prevention of myocardial infarction.

7. **AOB**

None

Date, time and venue of the next meeting

12th – 13th June 2012 from 10:00 – 4:00pm at the National Clinical Guideline Centre, 180 Great Portland Street, London